Regeneron’s 3Q EPS Beat Can’t Lift the Stock; Shares Down 4.5%
November 04, 2015 at 12:27 PM EST
Biotech giant Regeneron (REGN) posted 3Q EPS that beat expectations and raised U.S. sales guidance for its eye therapy, Eylea. Even CNBC’s Jim Cramer said the release “took my breath away.” So given the upbeat earnings report from last night, why isn’t Regeneron’s share price on the rise? The stock fell 4.5% to a recent […]
